BioWorld

April 13, 2010

View Archived Issues

Javelin Ending Myriad Merger; Gets Better Deal from Hospira

Read More

Legal 'Markmanship' at Play in Cubist/Teva Generic Fight

Read More

FDA Holds an 'Opening Day' as PDUFA V Debate Begins

Read More

ChemGenex's Omapro Delayed Pending Companion Diagnostic

Read More

Stock Movers

Read More

Clinic Roundup

Read More

Other News To Note

Read More

Financings Roundup

Read More

Appointments And Advancements

Read More

Mersana Inks $334M Teva Deal for Long-Acting Cancer Drug

Mersana Therapeutics Inc. is expected to announce on Tuesday a $334 million deal with Teva Pharmaceuticals Industries Ltd. for XMT-1107, a preclinical revival of the old antiangiogenic drug fumagillin. (BioWorld Today) Read More